Brian J Werth

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/838036/publications.pdf

Version: 2024-02-01

40 papers	1,215 citations	361413 20 h-index	395702 33 g-index
42 all docs	42 docs citations	42 times ranked	1254 citing authors

#	Article	IF	Citations
1	Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques. JAC-Antimicrobial Resistance, 2022, 4, dlac011.	2.1	8
2	New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides. Antimicrobial Agents and Chemotherapy, 2022, 66, e0261420.	3.2	19
3	Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization. Clinical Infectious Diseases, 2022, 75, 1641-1644.	5.8	12
4	Dalbavancin exposure inÂvitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection, 2021, 27, 910.e1-910.e8.	6.0	20
5	Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage. Journal of Antimicrobial Chemotherapy, 2021, 76, 292-296.	3.0	8
6	Varied Contribution of Phospholipid Shedding From Membrane to Daptomycin Tolerance in Staphylococcus aureus. Frontiers in Molecular Biosciences, 2021, 8, 679949.	3.5	3
7	Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant Staphylococcus aureus. Frontiers in Molecular Biosciences, 2021, 8, 688357.	3.5	7
8	Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx. Clinical Infectious Diseases, 2020, 71, 1877-1882.	5.8	14
9	National Consumption of Antimicrobials in Tanzania: 2017â€“2019. Frontiers in Pharmacology, 2020, 11, 585553.	3.5	21
10	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoeaâ€”challenges and opportunities. Clinical Microbiology and Infection, 2020, 26, 1630-1635.	6.0	16
11	Antimicrobial use across six referral hospitals in Tanzania: a point prevalence survey. BMJ Open, 2020, 10, e042819.	1.9	41
12	â€œSex in the Time of COVIDâ€: Clinical Guidelines for Sexually Transmitted Disease Management in an Era of Social Distancing. Sexually Transmitted Diseases, 2020, 47, 427-430.	1.7	26
13	Occurrence of cross-resistance and Î²-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. Journal of Antimicrobial Chemotherapy, 2020, 75, 1182-1186.	3.0	29
14	Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
15	Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1410-1414.	3.0	14
16	Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive Bacterial Pathogens by Multidimensional Lipidomics. MSphere, 2017, 2, .	2.9	87
17	Multidrug-ResistantCorynebacterium striatumAssociated with Increased Use of Parenteral Antimicrobial Drugs. Emerging Infectious Diseases, 2016, 22, .	4.3	51
18	Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry. Journal of Clinical Microbiology, 2016, 54, 883-890.	3.9	62

#	Article	IF	Citations
19	New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections. Clinical Infectious Diseases, 2016, 63, 281-282.	5.8	0
20	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 5716-5723.	3.2	37
21	Emergence of High-Level Daptomycin Resistance in Corynebacterium striatum in Two Patients with Left Ventricular Assist Device Infections. Microbial Drug Resistance, 2016, 22, 233-237.	2.0	37
22	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. Journal of Antimicrobial Chemotherapy, 2015, 70, 1272-1273.	3.0	1
23	Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. Journal of Antimicrobial Chemotherapy, 2015, 70, 489-493.	3.0	35
24	Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010. American Journal of Infection Control, 2015, 43, 465-468.	2.3	14
25	The combination of ampicillin plus ceftaroline is synergistic againstEnterococcus faecalis. Journal of Antimicrobial Chemotherapy, 2015, 70, 2414-2417.	3.0	12
26	Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics. Antimicrobial Agents and Chemotherapy, 2015, 59, 6132-6139.	3.2	3
27	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. Journal of Antimicrobial Chemotherapy, 2015, 70, 505-509.	3.0	36
28	A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 2989-2992.	3.2	36
29	Ceftaroline plus Avibactam Demonstrates Bactericidal Activity against Pathogenic Anaerobic Bacteria in a One-Compartment In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 559-562.	3.2	29
30	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. Journal of Antimicrobial Chemotherapy, 2014, 69, 2148-2154.	3.0	53
31	Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E. faecalis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5253-5261.	3.2	53
32	Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2014, 69, 3006-3010.	3.0	50
33	Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy, 2014, 58, 3177-3181.	3.2	44
34	Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the â€œseesaw effectâ€• Taking advantage of the back door left open?. Drug Resistance Updates, 2013, 16, 73-79.	14.4	55
35	Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 1565-1565.	3.2	2
36	Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA. Antimicrobial Agents and Chemotherapy, 2013, 57, 2376-2379.	3.2	62

#	Article	IF	Citations
37	Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 66-73.	3.2	118
38	Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the â€œSeesaw Effectâ€• Antimicrobial Agents and Chemotherapy, 2013, 57, 2664-2668.	3.2	54
39	Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy, 2012, 56, 5709-5714.	3.2	33
40	Reporting behaviors and perceptions toward the National Healthcare Safety Network antimicrobial use (AU) and antimicrobial resistance (AR) modules. Infection Control and Hospital Epidemiology, 0, , 1-7.	1.8	1